Disparities in human papillomavirus vaccine completion among vaccine initiators

Obstetrics and Gynecology

Volumn 118, Issue 1, 2011, Pages 14-20

  Chou, Betty ^a,b,c   Krill, Lauren S ^a,b,c   Horton, Bernice B ^a,b,c   Barat, Christopher E ^a,b,c   Trimble, Cornelia L ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c STEVENSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CHILD; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; RACE; URBAN AREA; VACCINATION;

ADOLESCENT; ADULT; AFRICAN AMERICANS; CHILD; FEMALE; HEALTH BEHAVIOR; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; INSURANCE, HEALTH; LOGISTIC MODELS; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; URBAN POPULATION; YOUNG ADULT;

EID: 79959679654     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318220ebf3     Document Type: Article

References (30)

1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 2006;24:S1-10.
2. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190:37-45. (Pubitemid 38858402)
3. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, Woodman CB. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-8.
4. American Cancer Society Statistics on Cervical Cancer. Available at: http://www.cancer.org/Cancer/CervicalCancer/Detailed Guide/cervical-cancer-key- statistics. Retrieved December 18, 2010.
5. McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control 2007;18: 1175-86. (Pubitemid 47498166)
6. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, Giuliano A. Incidence trends in invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 2009;20:1129-38.
7. Downs LS Jr, Scarinci I, Einstein MH, Collins Y, Flowers L. Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol 2010;117:486-90.
8. Fleurence RL, Dixon JM, Milanova TF, Beusterien KM. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007; 196:206-12. (Pubitemid 46341227)
9. Monk BJ, Herzog TJ. The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. Am J Obstet Gynecol 2007;197:337-9. (Pubitemid 47464170)
10. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20. (Pubitemid 39077963)
11. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23: 1107-22. (Pubitemid 41633402)
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
13. Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis 2006;43:624-9. (Pubitemid 44267125)
14. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. (Pubitemid 46977438)
15. Markovitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomvirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56(RR-2): 1-24.
16. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1018-23.
17. Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, Glynn S, et al. Human papillomavirus vaccine uptake, predic-tors of vaccination, and self-reported barriers to vaccination. J Women Health 2009;18:1679-86.
18. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009;84:864-70.
19. Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr 2009;48:966-9.
20. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010;28:989-95.
21. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009;27:6186-95.
22. Annual HPV vaccine uptake in England: 2008/2009. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/ PublicationsPolicyAndGuidance/DH-111675. Retrieved January 1, 2011.
23. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008;123:1854-63.
24. Opel DJ, Diekema DS, Marcuse EK. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics 2008;122:e504-10.
25. Hoops KE, Twiggs LB. Human papillomavirus vaccination: the policy debate over the prevention of cervical cancer-a commentary. J Low Genit Tract Dis 2008;12:181-4.
26. Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ. Initial lessons learned in HPV vaccination. Gynecol Oncol 2008;109: S4-11. (Pubitemid 351637606)
27. Dempsey A, Cohn L, Dalton V, Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine 2011;29:528-34.
28. Boughton B. Survey hints at uneven adoption of cancer vaccine. Nat Med 2008;14:5.
29. Castano PM, Martinez RA. Harnessing technology for adolescent health promotion. Adolesc Med State Art Rev 2007;18: 400-6.
30. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markovitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 2009; 48:426-31.